MSH Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.23M Buy
1,339
+4
+0.3% +$4.05K 0.26% 100
2025
Q4
$1.43M Sell
1,335
-46
-3% -$44K 0.31% 90
2025
Q3
$1.05M Hold
1,381
0.28% 94
2025
Q2
$1.08M Buy
1,381
+20
+1% +$15.5K 0.31% 89
2025
Q1
$1.12M Sell
1,361
-35
-3% -$29.1K 0.35% 81
2024
Q4
$1.08M Sell
1,396
-49
-3% -$40.6K 0.34% 79
2024
Q3
$1.28M Sell
1,445
-53
-4% -$47.6K 0.39% 76
2024
Q2
$1.36M Sell
1,498
-183
-11% -$146K 0.45% 69
2024
Q1
$1.31M Sell
1,681
-868
-34% -$618K 0.46% 70
2023
Q4
$1.49M Buy
2,549
+904
+55% +$528K 0.56% 59
2023
Q3
$884K Sell
1,645
-47
-3% -$24.2K 0.35% 86
2023
Q2
$794K Sell
1,692
-150
-8% -$62.9K 0.29% 95
2023
Q1
$633K Buy
1,842
+100
+6% +$33.7K 0.27% 100
2022
Q4
$637K Sell
1,742
-84
-5% -$29.8K 0.29% 97
2022
Q3
$590K Sell
1,826
-3
-0.2% -$951 0.29% 93
2022
Q2
$593K Hold
1,829
0.28% 93
2022
Q1
$524K Sell
1,829
-21
-1% -$5.41K 0.22% 107
2021
Q4
$511K Buy
+1,850
New +$469K 0.23% 104

Other funds holding LLY

MSH Capital Advisors's LLY Position: Q1 2026 in Review

MSH Capital Advisors increased its Eli Lilly (LLY) stake by 0.3% in Q1 2026, buying an estimated $4.05K and bringing the position to 1,339 shares worth $1.23M. The position accounts for 0.26% of the portfolio, ranked #100.

MSH Capital Advisors first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.49M in Q4 2023. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • MSH Capital Advisors held 1,339 shares of Eli Lilly worth $1.23M as of Q1 2026.
  • MSH Capital Advisors bought 4 Eli Lilly shares in Q1 2026, an estimated $4.05K.
  • Eli Lilly made up 0.26% of MSH Capital Advisors's portfolio in Q1 2026, its #100 holding.
  • MSH Capital Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • MSH Capital Advisors's Eli Lilly position peaked at $1.49M in Q4 2023.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on MSH Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.